BR112022005920A2 - USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 - Google Patents

USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2

Info

Publication number
BR112022005920A2
BR112022005920A2 BR112022005920A BR112022005920A BR112022005920A2 BR 112022005920 A2 BR112022005920 A2 BR 112022005920A2 BR 112022005920 A BR112022005920 A BR 112022005920A BR 112022005920 A BR112022005920 A BR 112022005920A BR 112022005920 A2 BR112022005920 A2 BR 112022005920A2
Authority
BR
Brazil
Prior art keywords
agent
seq
acute respiratory
respiratory syndrome
immunity against
Prior art date
Application number
BR112022005920A
Other languages
Portuguese (pt)
Inventor
Leonidovich Gintsburg Aleksandr
Sergeevich Semikhin Aleksandr
Sergeevna Erokhova Alina
Shahmirovna Dzharullaeva Alina
Ildarovich Tukhvatulin Amir
Gennadievich Botikov Andrei
Savelievich Naroditsky Boris
Mikhailovna Grousova Daria
Yuryevich Logunov Denis
Anatolievich Kutaev Dmitrii
Nikolaevich Shcherbinin Dmitrii
Viktorovich Shchebliakov Dmitrii
Alexandrovna Tokarskaya Elizaveta
Vladimirovich Kriukov Evgenii
Magomedovna Izhaeva Fatima
Bulatovich Esmagambetov Ilias
Vadimovna Dolzhikova Inna
Leonidovna Lubenets Nadezhda
Anatolievna Nikitenko Natalia
Mikhailovna Tukhvatulina Natalia
Olga Popova
Vadimovna Zubkova Olga
Yakovlevna Loginova Svetlana
Andreevna Ozharovskaia Tatiana
Aleksandrovich Chernetsov Vladimir
Fedorovich Babira Vladimir
Original Assignee
Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021104430A external-priority patent/RU2744442C1/en
Application filed by Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte filed Critical Federal State Budgetary Institution National Res Centre For Epidemiology And Microbiology Named Afte
Publication of BR112022005920A2 publication Critical patent/BR112022005920A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

uso do agente para indução de imunidade específica contra o vírus da síndrome respiratória aguda grave sars-cov-2. a presente invenção refere-se ao campo da biotecnologia, imunologia e virologia. o uso do agente é descrito, o dito agente contendo o componente 1, que é um agente na forma de vetor de expressão baseado no genoma da cepa recombinante de adenovírus humano soro-tipo 26 com sítios e1 e e3 deletados do genoma, e o sítio orf6-ad26 é substituído por orf6-ad5 com cassete de expressão integrado selecionado a partir de seq id no: 1, seq id no: 2, seq id no: 3, e/ou contendo um componente 2, que é um agente na forma de vetor de expressão baseado no genoma da cepa recombinante de adenovírus humano sorotipo 5 com sítios e1 e e3 deletados do genoma com cassete de expressão integrado selecionado a partir de seq id no: 1, seq id no: 2, seq id no: 3 para induzir imunidade específica contra o vírus da síndrome respiratória aguda grave sars-cov-2 em indivíduos acima de 60 anos de idade e/ou portadores de doenças crônicas.use of the agent to induce specific immunity against the severe acute respiratory syndrome virus sars-cov-2. The present invention relates to the field of biotechnology, immunology and virology. the use of the agent is described, said agent containing component 1, which is an agent in the form of an expression vector based on the genome of the recombinant strain of human adenovirus sero-type 26 with sites e1 and e3 deleted from the genome, and the site orf6-ad26 is replaced by orf6-ad5 with integrated expression cassette selected from seq id no: 1, seq id no: 2, seq id no: 3, and/or containing a component 2, which is an agent in the form of expression vector based on the genome of the recombinant strain of human adenovirus serotype 5 with sites e1 and e3 deleted from the genome with integrated expression cassette selected from seq id no: 1, seq id no: 2, seq id no: 3 for induce specific immunity against the severe acute respiratory syndrome virus sars-cov-2 in individuals over 60 years of age and/or with chronic diseases.

BR112022005920A 2021-02-21 2022-02-18 USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 BR112022005920A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2021104430A RU2744442C1 (en) 2021-02-21 2021-02-21 Use of agent for induction of specific immunity against severe acute respiratory syndrome sars-cov-2 for population revaccination in people over 60 and/or with chronic diseases (versions)
PCT/RU2022/000045 WO2022177465A1 (en) 2021-02-21 2022-02-18 The use of the agent for inducing immunity to sars-cov-2

Publications (1)

Publication Number Publication Date
BR112022005920A2 true BR112022005920A2 (en) 2023-11-07

Family

ID=82850909

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005920A BR112022005920A2 (en) 2021-02-21 2022-02-18 USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2

Country Status (9)

Country Link
EP (1) EP4294439A1 (en)
JP (1) JP2023507543A (en)
KR (1) KR20230175091A (en)
CN (1) CN115226392A (en)
BR (1) BR112022005920A2 (en)
CA (1) CA3156448A1 (en)
IL (1) IL291803B1 (en)
MX (1) MX2022004060A (en)
ZA (1) ZA202203564B (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2731342C9 (en) * 2020-08-22 2021-10-05 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Pharmaceutical agent and method for use thereof for inducing specific immunity to virus of severe acute respiratory syndrome sars-cov-2 (embodiments)

Also Published As

Publication number Publication date
IL291803B1 (en) 2024-03-01
KR20230175091A (en) 2023-12-29
CN115226392A (en) 2022-10-21
JP2023507543A (en) 2023-02-24
MX2022004060A (en) 2022-09-19
CA3156448A1 (en) 2022-08-21
EP4294439A1 (en) 2023-12-27
IL291803A (en) 2022-06-01
ZA202203564B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
BRPI0707543B8 (en) polypeptide composition and use thereof
BR112013005427A2 (en) immunogenic composition, vaccine, method for treating or preventing disease, and for preparing the immunogenic composition or vaccine, use of the vaccine, and pharmaceutical composition.
Oshansky et al. The human side of influenza
Roy et al. The Delta Plus variant of COVID-19: Will it be the worst nightmare in the SARS-CoV-2 pandemic?
BR112015030355A8 (en) use of a protein or an adenylyl cyclase type 6 (ac6) polypeptide incompetent with adenosine cyclic monophosphate (incompetent with camp) or a gene or nucleic acid encoding ac6mut, and, formulation
MX2022003069A (en) Agent for inducing specific immunity against sars-cov-2.
Shojaeefar et al. The possible double‐edged sword effects of vitamin D on COVID‐19: A hypothesis
BR112022016991A2 (en) METHODS FOR TREATING A HUMAN SUBJECT SUFFERING FROM CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME OR PNEUMONIA, FOR TREATMENT, PREVENTION, OR REDUCTION OF SEVERITY OR COAGULATION OR THROMBOSIS IN A HUMAN SUBJECT INFECTED WITH SERIOUS ACUTE RESPIRATORY SYNDROME CORONAVIRUS VIRUSES, IMPROVE, PREVENT OR REDUCE THE RISK OF DEVELOPING ONE OR MORE LONG-TERM SEQUELATES RELATED TO CORONAVIRUS
Murphy et al. Steroids for adult cardiac surgery with cardiopulmonary bypass: update on dose and key randomized trials
Liodaki et al. Epidemiology of pneumonia in a burn care unit: the influence of inhalation trauma on pneumonia and of pneumonia on burn mortality
BRPI0516542A (en) composition of vaccine effective in preventing or ameliorating infection with avian influenza virus; method to prevent or improve the outbreak of infection by avian influenza virus
BR112022005920A2 (en) USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2
BRPI0602397C1 (en) pharmaceutical compositions for the treatment of liver fat diseases, obesity and other diseases associated with the metabolic syndrome and methods of treatment using said compositions
BR112017013270A2 (en) "dengue virus vaccine composition, methods for inducing a dengue immune response, reducing the likelihood of dengue infection, or preventing or alleviating dengue symptoms, and use of a dengue virus vaccine composition."
BR112022004778A2 (en) AGENT FOR SPECIFIC IMMUNITY INDUCTION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARSCOV-2 IN LYOPHILIZED FORM (VARIANTS) AND USE
ZA202301438B (en) Aa v5-based vaccine against sars-cov-2
BR112022003581A2 (en) EXPRESSION VECTOR AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-COV-2
BR112022005967A2 (en) USE OF THE AGENT FOR INDUCTION OF SPECIFIC IMMUNITY AGAINST THE SARS-COV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS FOR POPULATION REVACCINATION (VARIANTS)
Chakraborty et al. Identification of promising CD8 and CD4 T cell epitopes for peptide vaccine formulation against SARS-CoV-2
BRPI0513118A (en) recombinant marek virus, vaccine and use of a virus
AR124744A1 (en) AGENT FOR USE IN INDUCING SPECIFIC IMMUNITY AGAINST SARS-CoV-2 SEVERE ACUTE RESPIRATORY SYNDROME VIRUS IN SUBJECTS OVER 60 YEARS OF AGE AND/OR HAVING CHRONIC DISEASES (VARIANTS)
AR124461A1 (en) AAV5-BASED VACCINE FOR THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SARS-CoV-2 AND/OR THE PREVENTION OF SARS-CoV-2-RELATED CORONAVIRUS INFECTION
AR124745A1 (en) AGENT FOR USE IN THE INDUCTION OF SPECIFIC IMMUNITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME VIRUS SARS-CoV-2 FOR POPULATION REVACCINATION (VARIANTS)
BR112022003611A2 (en) PHARMACEUTICAL AGENT TO INDUCE SPECIFIC IMMUNITY AGAINST SARS-COV-2
Hoft et al. The genetic archaeology of influenza